BACE1 and early-onset autosomal dominant Alzheimer disease: Systemically administered RVG-EVs loaded with exogenous siRNA produced strong mRNA (60%) and protein (62%) knockdown of BACE1, a therapeutic target in Alzheimer’s disease.